Stock Rich List
#2620 on the rich list of 14,644 insiders

Jean Jacques Bienaime

Director at BioMarin Pharmaceutical; Director at Incyte; Director at Ascendis Pharma A/S. Based in Lexington, Massachusetts.

$48.1M
in disclosed stock, −$74K (−0.15%) today
Market closed. Prices as of Nov 19, 4:04 PM ET
Rank
2620th of 14,644
Companies held
4
Largest holding
BMRN, 92.1% of total
Latest SEC filing
Aug 17, 2026
Listed but not counted
$742K

What the $48.1M is made of

Holdings counted

All filings on SEC.gov
CompanyHow heldSharesPriceValueShare of totalReported
BioMarin Pharmaceutical BMRN
Common Stock
Directly473,792$61.42$29.1M60.5%Form 4, May 20, 2024
BioMarin Pharmaceutical BMRN
Common Stock
Shares held by Jean-Jacques Bienaime Family Trust247,333$61.42$15.2M31.6%Form 4, May 20, 2024
Incyte INCY
Common Stock
Directly24,424$115.87$2.8M5.9%Form 4, Jun 8, 2026
Immunome IMNM
Common Stock
Directly43,415$16.61$721K1.5%Form 4, Jun 5, 2026
Keros Therapeutics KROS
Common Stock
Directly19,592$11.39$223K0.5%Form 4, Aug 17, 2026
BioMarin Pharmaceutical BMRN
Common Stock
Shares held as UTMA custodian for child 1100$61.42$6K0.0%Form 4, May 20, 2024

Share counts are the amounts Jean Jacques Bienaime reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.

Reported but not counted

These shares appear on Jean Jacques Bienaime's filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.

CompanyHow heldSharesPriceValueShare of totalReported
Ascendis Pharma A/S ASND
Ordinary Shares
Directly
Not valued: reported in home-market shares, which trade in the US as depositary shares at a different ratio
2,900$255.96$742K—Form 4, Aug 14, 2026

Open-market trades, last 12 months

DateTradeCompanySharesPriceValueFiling
Aug 17, 2026BoughtKROS1,000$10.27$10KView
Aug 14, 2026BoughtASND1,100$245.85$270KView
Aug 14, 2026BoughtASND900$246.91$222KView
Jul 15, 2026BoughtKROS1,000$10.61$11KView
Jun 15, 2026BoughtKROS1,000$10.19$10KView
Jun 5, 2026SoldIMNM500$19.44$10KView
Jun 5, 2026SoldIMNM10,000$19.41$194KView
Jun 5, 2026BoughtIMNM6,000$19.48$117KView
Jun 5, 2026BoughtIMNM3,500$19.46$68KView
Jun 5, 2026BoughtIMNM1,000$19.27$19KView
May 29, 2026BoughtASND200$223.76$45KView
May 29, 2026BoughtASND100$223.50$22KView
May 29, 2026BoughtASND200$222.30$44KView
May 26, 2026BoughtASND200$239.37$48KView
May 26, 2026BoughtASND200$236.24$47KView
May 15, 2026BoughtKROS1,000$10.58$11KView
May 15, 2026BoughtIMNM5,000$20.70$104KView
Apr 15, 2026BoughtKROS1,000$11.70$12KView
Mar 11, 2026BoughtIMNM1,000$21.55$22KView
Mar 10, 2026BoughtIMNM1,000$22.12$22KView
Mar 9, 2026BoughtKROS2,000$11.21$22KView

Nearby on the list

Full list
Nearby ranks
RankNameStock holdingsToday
2617Andrew S. Marsh
Chair and CEO, Entergy. New Orleans, LA
$48.1M−$824K (−1.69%)
2618Alexander M. Liberman
Chief Legal Officer, Medline. Northfield, IL
$48.1M−$1.7M (−3.37%)
2619David P. Poole
SVP & General Counsel, Range Resources. Morgantown, WV
$48.1M−$1.6M (−3.25%)
2620Jean Jacques Bienaime
Director, BioMarin Pharmaceutical. Lexington, MA
$48.1M−$74K (−0.15%)
2621Chris Rogers
President and CEO, Maplebear. San Francisco, CA
$48.1M−$681K (−1.40%)
2622Stacey Friedman
General Counsel, JPMorgan Chase &. New York, NY
$48.1M−$584K (−1.20%)
2623Charlotte Guyman
Director, Berkshire Hathaway. Medina, WA
$48.0M−$248K (−0.51%)

Other BioMarin Pharmaceutical insiders

All BMRN insiders

Questions

How much stock does Jean Jacques Bienaime own?

Jean Jacques Bienaime holds $48,071,924 in listed stock based on SEC filings and current prices, mostly BioMarin Pharmaceutical (BMRN). That ranks 2620th on the Stock Rich List.

Is this Jean Jacques Bienaime's net worth?

No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.

When did Jean Jacques Bienaime last buy or sell stock?

The most recent open-market trade on file is a purchase of 1,000 KROS shares on Aug 17, 2026 at $10.27.